[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369422-105":59,"doc-detail-369422-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","real-world-treatment-patterns-and-outcomes-among-patients-with-early-non-small-cell-lung-cancer-mdpi-article-summary","Real-World Treatment Patterns and Outcomes Among Patients with Early Non-Small Cell Lung Cancer - MDPI Article Summary","","The article examines how targeted therapies and systemic treatment are adopted for patients with early non-small cell lung cancer (eNSCLC, stages I–IIIA), where their real-world impact remains insufficiently characterized. A retrospective observational study uses a US nationwide electronic health record-derived deidentified database (January 2019–March 2024) to detail demographics, neoadjuvant and adjuvant use, and patient outcomes. Among 4,841 stage IB–IIIA patients, definitive therapy predominated, yet adjuvant use was limited and neoadjuvant use was rarely included. Survival was lower for radiation or chemoradiation patients without systemic therapy, supporting improved utilization of perioperative systemic treatment.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-treatment-patterns-and-outcomes-among-patients-with-early-non-small-cell-lung-cancer-mdpi-article-summary/369422/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-treatment-patterns-and-outcomes-among-patients-with-early-non-small-cell-lung-cancer-mdpi-article-summary/369422.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What study data and period were used to assess treatment patterns and outcomes?","Question",{"text":113,"@type":114},"The study is retrospective and uses a US nationwide electronic health record-derived deidentified database covering January 2019 to March 2024.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How common were neoadjuvant therapies in this early NSCLC population?",{"text":118,"@type":114},"Neoadjuvant use was limited across groups, with rates reported as 8.2% for surgery patients, 6.1% for radiation patients, and 11.6% for chemoradiation patients.",{"name":120,"@type":111,"acceptedAnswer":121},"Which systemic therapies were most common among patients receiving definitive radiation or chemoradiation?",{"text":122,"@type":114},"Immune checkpoint inhibitors were the most common choice for definitive radiation (39.1%) and chemoradiation (73.7%) patients.",{"name":124,"@type":111,"acceptedAnswer":125},"What outcome differences did the study observe when systemic therapy was not used?",{"text":126,"@type":114},"Patients receiving definitive chemoradiation or radiation without systemic therapy showed lower survival rates compared with surgical patients, whose outcomes were similar across groups.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},369422,1790471458,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nReal-World Treatment Patterns and Outcomes Among Patients with Early Non-Small Cell Lung Cancer  \nJennifer D. Deem 1, *, Zsolt Hepp 2 and Joshua J. Carlson 1  \nReceived: 25 February 2025  \nRevised: 10 April 2025  \nAccepted: 16 April 2025  \nPublished: 19 April 2025  \nCitation: Deem, J.D.; Hepp, Z.; Carlson, J.J. Real-World Treatment Patterns and Outcomes Among Patients with Early Non-Small Cell Lung Cancer. Curr. Oncol. 2025, 32, 239. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol32040239  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA 98195, USA; [carlsojj@uw.edu](carlsojj@uw.edu)  \n[2](2) Pfizer Inc., New York, NY 10001, USA; zsolt.hepp@pfizer.com  \n* Correspondence: [dezet74@uw.edu](dezet74@uw.edu)  \nAbstract: Worldwide, about two million people are diagnosed with lung cancer each year, 85% of whom have non-small cell lung cancer (NSCLC) . Recent progress in treating advanced/metastatic NSCLC with targeted therapies has shifted attention to early NSCLC (Stages I–IIIA) and perioperative (neoadjuvant and adjuvant) systemic therapies. However, our comprehension of how targeted therapeutics are incorporated into care and their impact on patient outcomes is just starting to unfold. Methods: This retrospective observational study used a US nationwide electronic health record-derived deidentified database spanning January 2019–March 2024 and aimed to describe (1) eNSCLC patient demographic and clinical characteristics,(2) real-world neoadjuvant and adjuvant use, and (3) patient outcomes. Results: The study population included 4841 Stage IB–IIIA NSCLC patients with a mean age of 70.9 ± 8.6 years. The majority (69.9%) received definitive treatment: surgery (n = 2280), definitive radiation (n = 320), or definitive chemoradiation (n = 783), while 30.1%(n = 1458) did not. Many definitive treatment patients received some perioperative systemic therapy (surgery: 52.6%, radiation: 52.2%, chemoradiation: 75.5%) . Neoadjuvant use was limited in all groups (surgery: 8.2%, radiation: 6.1%, chemoradiation: 11.6%) . Among the 54.6% receiving adjuvant, immune checkpoint inhibitors were the most common choice for definitive radiation (39.1%) and chemoradiation (73.7%) patients, while surgical patients predominantly received platinum-doublet therapy (37.0%) . Surgical patient outcomes were similar across all groups, while definitive chemoradiation or radiation patients without systemic therapy had lower survival rates. Conclusions: In this study, we found that although the majority of patients underwent some form of definitive treatment, adjuvant use was limited, and neoadjuvant use was rarely included in care. A crucial initial step in improving patient outcomes is to understand and address the underutilization of neoadjuvant/adjuvant systemic therapy for eNSCLC patients.  \nKeywords: early NSCLC; treatment patterns; real-world; patient outcomes  \n1. Introduction  \nLung cancer, the third most common cancer diagnosis and leading cause of cancer deaths in the US, is a significant health concern. About 85% of those diagnosed have non-small cell lung cancer (NSCLC), which is predominantly composed of either squamous or non-squamous (adenocarcinoma) subtypes, while the remaining fraction has large cell carcinoma. These histologically unrelated cancers have historically been treated similarly [1,2] . Over the last 15 years, targeted systemic treatments, including immunotherapy (IO), tyrosine kinase inhibitors (TKIs), and immune checkpoint inhibitors (ICIs), have improved survival from months to years in advanced NSCLC [2–4] . Due to thei","cbCaih8nigkb2Mdo","https://ap.wps.com/l/cbCaih8nigkb2Mdo","pdf",1591642,18,"English","# Introduction\n## Rationale for studying early NSCLC treatment\n# Methods and Study Design\n## Data source and retrospective observational approach\n# Results\n## Patient characteristics and definitive treatment use\n## Neoadjuvant and adjuvant systemic therapy patterns\n## Outcome comparisons by treatment approach\n# Conclusions\n## Key findings and implications for practice","[{\"question\":\"What study data and period were used to assess treatment patterns and outcomes?\",\"answer\":\"The study is retrospective and uses a US nationwide electronic health record-derived deidentified database covering January 2019 to March 2024.\"},{\"question\":\"How common were neoadjuvant therapies in this early NSCLC population?\",\"answer\":\"Neoadjuvant use was limited across groups, with rates reported as 8.2% for surgery patients, 6.1% for radiation patients, and 11.6% for chemoradiation patients.\"},{\"question\":\"Which systemic therapies were most common among patients receiving definitive radiation or chemoradiation?\",\"answer\":\"Immune checkpoint inhibitors were the most common choice for definitive radiation (39.1%) and chemoradiation (73.7%) patients.\"},{\"question\":\"What outcome differences did the study observe when systemic therapy was not used?\",\"answer\":\"Patients receiving definitive chemoradiation or radiation without systemic therapy showed lower survival rates compared with surgical patients, whose outcomes were similar across groups.\"}]","Real-World Treatment Patterns and Outcomes Among Patients with Early Non-Small Cell Lung Cancer - MDPI Article Summary | PDF",1790182583,45,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8fe7f97cdee9cc4f22dd84445432fa5.webp",983,1390,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/910f031f714905a8d251602fe95d6264.webp",982,1388,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0623c1530d1d31315cc8a2759802ac7e.webp",981,1387,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/821482f7d30f2bb5eae65f76fc62df0f.webp",980,1385]